Cargando…

A Rare Case of ALK-Positive Large B-Cell Lymphoma with CD33 Expression

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a very rare and aggressive subtype of diffuse large B-cell lymphoma characterized by ALK rearrangement. Immunophenotypically, the tumor cells are typically negative for common B-cell markers, T-cell markers, and CD30; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Corean, Jessica, Li, K. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016151/
https://www.ncbi.nlm.nih.gov/pubmed/29992063
http://dx.doi.org/10.1155/2018/5320590
Descripción
Sumario:Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a very rare and aggressive subtype of diffuse large B-cell lymphoma characterized by ALK rearrangement. Immunophenotypically, the tumor cells are typically negative for common B-cell markers, T-cell markers, and CD30; however, they express markers of terminally differentiated B cells/plasma cells such as CD38, CD138, and MUM-1/IRF4. The diagnosis of ALK+ LBCL can be challenging, and often a large panel of immunostains is required to exclude other hematopoietic and nonhematopoietic neoplasms. To date, approximately 130–140 cases have been reported, but here we report the first known case of ALK+ LBCL with unusual CD33 expression.